OFIX earnings analysis
What we found in OFIX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Orthofix delivered Q2 revenue of $210.9M, up 3.8% year over year and above Q1's $197M, with a 230-basis-point gross-margin expansion to 71.0% and a 400-basis-point operating-margin improvement to negative 3.9%. Limb Reconstruction was the principal growth driver at 13.2%, while Global Spine grew 2.0% despite the discontinued M6 products and temporary Medicare-related pricing pressure. The operating improvement was offset by a $15.8M GAAP net loss, higher interest expense, and negative six-month free cash flow of $47.1M; leverage stood at $225.0M.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue returned to sequential growth
- Q2 net sales were $210.9M, up $7.8M, or 3.8%, from $203.1M a year earlier. Sales also increased from $197M in Q1 2026.
- Material year-over-year margin recovery
- Gross margin expanded 230 basis points year over year to 71.0% from 68.7%, while operating margin improved 400 basis points to negative 3.9% from negative 7.9%. Gross profit rose $10.2M to $149.7M.
- Limb Reconstruction led segment growth
- Global Limb Reconstruction revenue grew 13.2% to $37.7M, including a $3.5M international increase and a $0.7M favorable foreign-exchange benefit.
- Core Spine categories grew despite M6 exit
- Global Spine sales reached $173.2M, up $3.4M year over year; Therapeutic Solutions grew $1.6M to $64.2M and Spinal Implants, Biologics and Enabling Technologies rose $4.2M excluding M6.
- Cash balance increased following financing
- Cash, cash equivalents and restricted cash increased to $104.4M at June 30, 2026 from $85.1M at December 31, 2025, supported by $66.4M of financing cash flow.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- New FDA reclassification competition risk
- The filing added a risk factor that the FDA's reclassification of bone-growth stimulators from Class III to Class II could lower barriers for competitors. Therapeutic Solutions generated $64.2M of Q2 sales, making potential price and share pressure material.
- Cash burn and inventory efficiency weakened
- Six-month operating cash flow was negative $23.8M and capital expenditures were $23.3M, producing negative $47.1M free cash flow versus negative $20.6M a year earlier. Inventory turns fell to 1.3x from 1.5x.
- Higher debt increased interest burden
- Outstanding credit-facility borrowings were $225.0M at June 30, 2026, after the $65.0M Term B Loan was funded in January. Quarterly net interest expense increased $2.1M to $6.1M.
- EPS loss widened year over year
- GAAP net loss was $15.8M and diluted EPS was negative $0.39, versus negative $0.36 in Q2 2025. Other income/expense deteriorated $6.5M year over year and interest expense rose $2.1M.
- Medicare reimbursement disruption affected pricing
- Therapeutic Solutions' $1.6M growth was partly offset by unfavorable pricing from Medicare billing and fee-schedule changes effective May 18, 2026, although CMS withdrew the changes on July 1, 2026.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.39
- Gross margin
- 71.0%
- Operating margin
- -3.9%
- Segment
- Global Spine: $173.2M, up $3.4M (2.0%) reported year over year; $167.4M pro forma prior-year comparison.
- Segment
- Global Limb Reconstruction: $37.7M, up $4.4M (13.2%) year over year.
What they said about what is next.
The 10-Q does not provide explicit quantitative annual revenue or EPS guidance; outlook was deferred to other company communications.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 5, 2026
- Orthofix Medical Inc. reported Q1 2026 revenue of $196.7 million, slightly exceeding the estimate of $194.7 million, while recording a diluted EPS loss of $(0.52), which surpassed the expected loss of $(0.38). The…
- 10-K · February 24, 2026
- Orthofix describes a spine-centric strategy focused on organic and inorganic innovation, sales-channel optimization, and clinical evidence to drive growth; Global Spine accounted for 84% of net sales in 2025.…
- 10-Q · November 7, 2024
- Orthofix reported net sales of $196,606,000 for the quarter ended September 30, 2024, up from $184,006,000 in Q3 2023, with gross profit increasing to $135,053,000 and gross margin expanding to ~68.7%. Operating loss…
- 10-Q · August 6, 2024
- Orthofix reported net sales of $198,620 for the quarter ended June 30, 2024, up $11,604 versus $187,016 in Q2 2023. Gross profit increased to $134,749 (gross margin ~67.9%) and operating loss narrowed to $(24,906) from…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing OFIX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever